key: cord-0902616-6cttboh8
authors: Martora, Fabrizio; Fabbrocini, Gabriella; Picone, Vincenzo
title: A case of herpes zoster ophthalmicus after third dose of Comirnaty (BNT162b2 mRNA) vaccine
date: 2022-03-04
journal: Dermatol Ther
DOI: 10.1111/dth.15411
sha: 255962353831e720f3d55071f77318c4f00a9f38
doc_id: 902616
cord_uid: 6cttboh8

nan

A case of herpes zoster ophthalmicus after third dose of Comirnaty (BNT162b2 mRNA) vaccine Dear Editor,

The SARS-CoV-2 pandemic has afflicted the world in these 2 years. In Italy, the vaccination campaign has now reached the third dose. The third dose was initially directed to immunocompromised patients, but now it can be administered to patients who have received the second dose for at least 4 months. 1 The side effects related to the administration of vaccines most described in the literature are fever, redness, pain and tenderness at the injection site, musculoskeletal pain and headache. 2 Several cutaneous adverse events after anti-COVID-19 vaccination are described in the literature, such as delayed large local reaction, urticaria, morbilliform eruptions, herpes zoster, "COVID arm," pityriasis rosea. 3, 4, 5 Here, we report a case of a patient who presented with herpes zoster ophthalmicus (HZO) after the third dose of the Comirnaty (BNT162b2 mRNA) vaccine (Pfizer). Elderly individuals are at greater risk of developing HZO, because age-related immunosenescence is the major risk factor for this condition. 6 HZO is a disabling condition because it can impair patients' vision. 7 Corneal lesions and uveitis are the most frequently associated manifestations and can cause blindness if not treated in time. 6, 7 There are few cases of HZO after anti-SARS-CoV-2 vaccine mRNAs in the literature. 7, 8 Although the pathophysiologic mechanism underlying this correlation is still poorly understood, it is hypothesized that the vaccine may slatentize VZV in some patients, particularly in the elderly with an immunosenescent condition. 5, 7 We believe it is important to report our case for the literature, especially because in view of the third dose aimed primarily at immunocompromised patients, the risk of developing adverse reactions is certainly increased. However, given the responsiveness to systemic antiviral treatments, we believe that the risk-benefit ratio is clearly in favor of vaccination and possible side effects should not hinder the global vaccination campaign.

We believe that further studies on this topic are needed to confirm these hypotheses.

F I G U R E 1 Vescicular eruption along the first and second trigeminal branches (V1 and V2) with dermatomeral distribution

Covid-19: UK will offer third vaccine dose to severely immunosuppressed people

Safety and efficacy of the BNT162b2 mMRNA COVID-19 vaccine

Covid arm": abnormal side effect after Moderna COVID-19 vaccine

Pityriasis rosea after Moderna mRNA-1273 vaccine: a case series

Herpes zoster after ChAdOx1 nCoV-19 vaccine: a case series

Herpes zoster ophthalmicus review and prevention

Varicella-zoster virus reactivation causing herpes zoster ophthalmicus (HZO) after SARS-CoV-2 vaccination-report of three cases

Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series